Taro Updates Shareholders on Financial Turnaround; Projects Significant Growth in Net Sales in 2008; Reaffirms Board's ... (Centre Daily Times)
Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) today announced that it is sending a letter to its shareholders updating them on the status of the Company's financial and operational turnaround.

FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals (Centre Daily Times)
Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) has received a not approvable letter for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia, from the U.S. Food and Drug Administration (FDA). Vanda, the sub-licensee for iloperidone, is responsible for the development and commercialization of this product.